Tuis300601 • SHE
add
Shenzhen Kangtai Biological Prods Co Ltd
Vorige sluiting
¥16,79
Dagwisseling
¥16,65 - ¥16,90
Jaarwisseling
¥13,10 - ¥21,39
Markkapitalisasie
18,38 mjd CNY
Gemiddelde volume
19,63 m
P/V-verhouding
336,56
Dividend-opbrengs
0,54%
Primêre beurs
SHE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 746,86 m | -0,47% |
Bedryfskoste | 545,63 m | 14,03% |
Netto inkomste | 15,10 m | -86,43% |
Netto winsgrens | 2,02 | -86,38% |
Wins per aandeel | — | — |
EBITDA | 41,21 m | -73,10% |
Effektiewe belastingkoers | 156,17% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,44 mjd | 221,80% |
Totale bates | 14,13 mjd | -2,19% |
Totale aanspreeklikheid | 4,53 mjd | -7,75% |
Totale ekwiteit | 9,60 mjd | — |
Uitstaande aandele | 1,12 mjd | — |
Prys om te bespreek | 1,95 | — |
Opbrengs op bates | -1,00% | — |
Opbrengs op kapitaal | -1,23% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 15,10 m | -86,43% |
Kontant van bedrywe | 121,90 m | -8,83% |
Kontant van beleggings | 62,96 m | -23,54% |
Kontant van finansiering | -187,09 m | 75,28% |
Netto kontantverandering | -2,37 m | 99,56% |
Beskikbare kontantvloei | 2,56 mjd | 636,57% |
Meer oor
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
Gestig
08 Sep. 1992
Webwerf
Werknemers
1 913
